Literature DB >> 9649976

Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.

J Bearn1, M Gossop, J Strang.   

Abstract

This open study compares an accelerated 5-day lofexidine regimen with orthodox 10-day lofexidine and methadone regimens in the treatment of opiate withdrawal in 61 polysubstance abusing opiate addicts. Significant differences in levels of withdrawal symptoms were found on days 11, 13-15 and 17-20, symptoms resolving most rapidly in the 5-day lofexidine treatment group, whilst withdrawal responses in the 10-day lofexidine treatment group were intermediate between the 5-day lofexidine and standard methadone treatment conditions. When the two lofexidine regimens were separately compared with methadone the 5-day lofexidine treatment was significantly more effective on day 10, 11 and 13-20, whilst the 10-day lofexidine treatment was not significantly different from methadone. There were no significant differences in rates of completion of detoxification between the three treatments. Both the lofexidine treatment regimens had a similar effect on blood pressure. Five patients experienced side effects which resolved with dose reduction, all remaining in the study. An accelerated 5-day lofexidine regimen may attenuate opiate withdrawal symptoms more rapidly than conventional 10-day lofexidine or methadone treatment schedules without exacerbating hypotensive side effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649976     DOI: 10.1016/s0376-8716(98)00030-1

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  Opiate detoxification under anaesthesia. No confusion and distress were intended.

Authors:  J Strang; J Bearn; M Gossop
Journal:  BMJ       Date:  1999-07-31

2.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

Review 3.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

Review 4.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 5.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-27       Impact factor: 4.530

Review 7.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 8.  Treatment of heroin (diamorphine) addiction: current approaches and future prospects.

Authors:  Gerardo Gonzalez; Alison Oliveto; Thomas R Kosten
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

Review 10.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.